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Objectives: This study aimed to analyze incidence and mortality trends in breast cancer (BC), 
corpus uteri cancer (CUC), and ovarian cancer (OC) in Poland in the context of sociodemo-
graphic changes.
Materials and methods: Incidence and mortality data (1980–2013) were retrieved from the 
Polish National Cancer Registry, while socioeconomic data (1960–2013) were obtained from 
the World Bank. Age-standardized incidence and mortality rates were calculated by direct 
standardization, and join-point regression was performed to describe trends using the average 
annual percentage change (AAPC).
Results: A significant decrease in birth and fertility rates and a large increase in gross domestic 
product were observed together with a decrease in the total mortality rate among women, as 
well as an increase in life expectancy for women. A large, significant increase in BC incidence 
was observed (AAPC
1980–1990
 2.14, AAPC
1990–1996
 4.71, AAPC
1996–2013
 2.21), with a small but 
significant decrease in mortality after a slight increase (AAPC
1980–1994
 0.52, AAPC
1994–2013
 -0.66).
During the period 1980–2013, a significant increase in CUC incidence (AAPC
1980–1994
 3.7, 
AAPC
1994–2013
 1.93) was observed, with an initial mortality-rate reduction followed by a sig-
nificant increase (AAPC
1980–2006
 -1.12, AAPC
2006–2013
 3.74). After the initial increase of both OC
incidence and mortality from 1994, the incidence rate decreased significantly (AAPC
1980–1994
 2.98, 
AAPC
1994–2013
 -0.49), as did the mortality rate (AAPC
1980–1994
 0.52, AAPC
1994–2013
 -0.66).
Conclusion: After 1994, a decrease in OC incidence was found, while the incidence of BC 
and CUC continued to increase. A reduction in mortality rate was observed for BC and OC 
predominantly at the end of the study period, while for CUC, after a long decreasing mortality 
trend, a significant increase was observed.
Keywords: average annual percentage change, breast cancer, corpus uteri cancer, epidemiology, 
incidence, mortality, ovarian cancer
Introduction
Breast cancer (BC), corpus uteri cancer (CUC), and ovarian cancer (OC) are the top 
three malignancies related to female genital organs that predominate in high-income 
countries.1,2 Political and economic changes in Poland that occurred after political 
regime transformation in the year 1989 resulted in increasing gross domestic income 
and redefinition of national health care strategy, with increasing access to medica-
tions (including hormonal contraception), diagnostic procedures, and treatment 
facilities.3 However life style changes, that occurred after political transformation, 
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led unfortunately to growing incidence of cardiovascular 
diseases, diabetes, overweight, and decreased parity, 
which are observed in welfare populations.4–6 Political and 
economic changes significantly affected socioeconomi-
cally dependent behaviors and lifestyle, which influenced 
significantly risk factors of malignancies, including BC, 
CUC, and OC.
BC is the most common female malignancy, with peak 
incidence after 40 years of age. Fortunately, in the developed 
world a steady decline in BC deaths has been observed since 
1990 at a rate of 3.3% in patients under 51 years and 2% per 
year in elderly women.2 Factors associated with increased 
estrogen exposure, such as early menarche, late menopause, 
delayed first pregnancy, or nulliparity, have been reported to 
increase the risk of BC.7 Short-term breast-feeding or lack of 
breast-feeding as a result of nulliparity were also associated 
with increased risk of BC.8 Obesity and postmenopausal 
weight gain were the two important modifiable risk factors 
for BC identified in prospective observational studies.9 Prior 
radiation exposure, high breast density, history of biopsies for 
benign breast conditions, and genetic mutations, including 
BRCA1 and BRCA2, have also proved to be nonmodifiable 
risks of BC independently of lifestyle and socioeconomic 
background.10,11
In the developed world, CUC is the most commonly 
diagnosed malignancy of reproductive tract and the 
fourth-most frequently diagnosed cancer among American 
females.2 Over 90% of CUCs are epithelial tumors. Based 
on clinical, histological, and molecular features, two types 
of endometrial cancers are distinguished. Estrogen-depen-
dent type I tumors account for 85% of cases and include 
endometrioid endometrial cancer, which tends to occur 
in younger women suffering from obesity, diabetes often 
nulliparous but have favorable prognosis, while estrogen-
independent type II endometrial cancers, such as serous, 
clear-cell, and high-grade endometrioid adenocarcinoma, 
occur predominantly around the age of 70 years and are 
characterized by poorer survival.2 Up to 8% of CUCs are 
mesenchymal tumours.12
OC is the sixth-most common malignancy in women 
and the leading cause of death in well-developed countries.2 
Ovarian epithelial neoplasms, including borderline ovarian 
tumors, constitute up to 90% of ovarian malignancies, with 
established risk factors including increasing age with peak 
incidence at 70 years, family history of ovarian and/or BC, 
nulliparity, and tobacco smoking, while use of hormonal 
contraception, long breast-feeding, multiparity, fallopian tube 
ligation or excision, and hysterectomy are proven protective 
factors against this cancer.13–16 Generally, ovarian epithelial 
malignancies (excluding borderline tumors) represent an 
unfavorable prognosis, with an average 5-year survival rate 
of 45%.17 Ovarian germ-cell tumors account for 2%–3% of 
OCs, and occur usually at a young age, with peak incidence 
in the early 20s.18 No significant risk factors for germ-cell 
ovarian tumors have been identified, as 95% of them occur in 
normal gonads.18 Approximately 7% of ovarian malignancies 
are sex cord-stromal tumors, with a significant proportion 
diagnosed before 40 years of age and the ability to produce 
a broad variety of steroids and hormones with unidentified 
predisposing factors.19
From well-identified risk factors for BC, CUC, and OC 
we can distinguish these depending on lifestyle. As there 
is evidence of increasing lifestyle-related diseases, such as 
obesity, hypertension, and diabetes, in the Polish population, 
we asked a question concerning the incidence and mortality 
of the three most common female genital organ malignan-
cies with proven lifestyle-dependent risk factors during the 
period 1980–2013 that included rapid economic growth.4–6 
As high-income populations are at risk of different gyneco-
logical cancers compared to lower-income countries, using 
data from a population-based registry, we aimed to provide 
information regarding incidence and mortality trends for BC, 
CUC, and OC in Poland from 1980 to 2013 in the context of 
socioeconomic changes in 1989.1
Materials and methods
Data sources
Gross domestic product (GDP) per capita was used as 
an indicator of economic growth, while crude birth rate 
(per 1,000 persons) and fertility rate (average number of 
births during a woman’s life span) were used to evaluate 
economic and reproductive trends. Given that exposure to 
risk factors can precede the occurrence of cancer by decades, 
data from 1960–2013 were used to analyze macroeconomic 
and reproductive trends. The data were retrieved from the 
World Bank database, which is compiled from officially 
recognized international sources (http://data.worldbank.org/
data-catalog/world-development-indicators).
Data on the incidence of cancer and mortality rates for 
1980–2013 were retrieved from the Polish National Cancer 
Registry (PNCR). Diagnoses made between 1980–1996 
were coded using the International Statistical Classification 
of Diseases and Related Health Problems (ICD), ninth revi-
sion: ICD 174 for female BC, ICD 182 for CUC, and ICD 
183 for OC. Data after 1996 were coded according to the 
ICD, tenth revision: C50 for female BC, C54 for CUC, and 
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C56 for OC. Unfortunately, data for 1981 and 1986–1987 
were unavailable for research and data from 1997–1998 were 
missing, due to strikes by medical staff during that period. 
The study was approved by the Jagiellonian University 
Review Board.
statistical analyses
The world standard population was used to calculate the 
age-standardized rates for cancer incidence and mortality.20 
A join-point regression analysis using the Joinpoint 
Regression program, version 4.0.1 (Information Management 
Services Inc, Rockville, MD, USA) was performed to 
determine the incidence and mortality trends. The analysis 
included a logarithmic transformation of the rates, standard 
errors, and a maximum number of five join points with a 
minimum of 4 years between two join points.21,22 This method 
allowed for the identification of join points based on regres-
sion models with 0–5 join points and for the selection of the 
final best-fitting model, with the estimated annual percentage 
change (EAPC) based on the trend within each segment. The 
APC was subsequently calculated to quantify the trend over 
a fixed number of years as a geometric weighted average 
of the EAPC-trend analysis, with the weights equal to the 
lengths of each segment during the prespecified fixed inter-
val. When the slope of the whole trend was statistically sig-
nificant (P0.05), the trend was described as “significantly 
increasing” or “significantly decreasing”. In other cases, the 
terms “stable” (for an APC between -0.5 and 0.5 inclusive), 
“non-statistically significant increase” (for an AAPC of 
0.5; P0.05), and “non-statistically significant decrease” 
(for an APC of -0.05, P0.05) were used. Trend-line 
slopes were arbitrarily considered low if 0.5 average APC 
(AAPC) 1, moderate if 1 APC 3, and high if AAPC 
3. All statistical tests were two-sided. The trend data were 
showed as APC values with 95% confidence intervals.
Results
Macroeconomic data and reproductive 
trends
The GDP increased from 1960 (US$3,000 purchasing power 
parity) to 2013 ($12,000 purchasing power parity). Between 
1975 and 1989, the GDP per capita was stable at around 
$6,000, and after a slight decrease in the early 1990s, the 
GDP began steadily increasing year to year, and doubled in 
the next 20 years (until 2013).
During that period, we also observed an increase in average 
life expectancy of women (70.4–82.1 years), while the crude 
mortality rate for women decreased from 121.8 to 76.1 per 
1,000 (Figure 1). The crude birth rate fluctuated, but an increase 
was observed between 1970 and 1984 (Figure 2). On the other 
hand, a significant drop in fertility rate was observed from 
1960 to 2013, except for 1968–1984 and 2003–2009, when a 
significant increase was noted (Figure 2).
Female breast cancer
A significant increase in the incidence of female BC was 
observed during the analyzed period. Between 1980 and 
1990, the AAPC for incidence was 2.14 (P0.05), and a two-
fold increase in AAPC was observed (reaching 4.71, P0.05) 
between 1990 and 1996, with a subsequent decrease from 
1996 to 2013 to (2.21, P0.05). From 1980 to 1994, a slight 
but significant increase in BC mortality rate was observed 
(AAPC 0.52, P0.05). However, the mortality rate started 
to decrease after 1994 (AAPC -0.66, P0.05) (Table 1, 
Figure 3). On the other hand, analysis of the incidence of 
female BC by age-group showed an increase in almost all 
groups, except women aged 20–24 years and women aged 
45–49 years in 1980–1983. In the remaining age-groups, the 
AAPC varied from 0.27 to 11.37 depending on age and time 
period, with the highest significant value observed among 
women aged 55–59 years in 1992–2001 (6.66, P0.05, 
Figure 1 Trends in female mortality rates (crude values) and life expectancy, 1960–2013.
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Table 2). We also observed a significant decrease in mortality 
trends in women aged 25–39 years, with significant AAPC 
values between -3.12 and -1.82 (Table 2). Interestingly, 
among women aged 40–59 years, increasing trends in BC 
mortality were observed until the mid- to late 1990s, after 
which a significant decrease was seen (Table 2). For women 
aged 60–69 years, the BC mortality rate was stable through-
out the study period (Table 2). In patients aged 70–84 years, 
a bimodal trend was shown for BC mortality, with a signifi-
cantly increasing AAPC at the beginning of the study period 
followed by an insignificant decrease (Table 2).
corpus uteri cancer
CUC incidence varied from 6.6 to 13.7 while the mortality 
rate ranged from 2 to 2.8. A significantly high increase in 
CUC incidence was observed from 1980 to 1994 (AAPC 
3.70, P0.01) and continued at a lower level until 2013 
(AAPC 1.93, P0.01) (Table 1, Figure 3). The mortality 
rate increased significantly from 1980 to 1989 (AAPC 1.13, 
P0.05), then stabilized until 2009 (AAPC 0.19, P0.05) 
and decreased (insignificantly) until the end of the study 
(AAPC -1.6, P0.05) (Table 1, Figure 3). Analysis of 
CUC incidence by age-group confirmed an increase for all 
age-groups, except women aged 60–64 and 80–84 years, 
who showed a large decrease in CUC incidence from 1980 
to 1983 (Table 2).
Age-specific trend lines for mortality related to CUC 
across age-groups reflected a significant decline among those 
aged 40–44, 45–49, and 50–54 years. A continuous increase 
in mortality rate during the study period was observed only in 
women aged 85+ years. In women aged 55–59, 70–74, 75–79, 
and 80–84 years, the mortality rate remained insignificant and 
moderately decreased until the early 2000s, then increased 
in the last years of the observation period. For women aged 
60–64 and 65–69 years, after an initial increase in mortality 
due to CUC, we observed a gradual decrease in mortality in 
− − −
− − −
− − −
− − −
− − −
−
− − −
− − −
Figure 2 Trends in the crude birth rate (per 1,000 persons) and fertility rate (average number of births during a woman’s life span), 1960–2013.
Note: $P0.05.
Abbreviations: AAPC, average annual percentage change; CI, confidence interval.
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the mid-study period, followed by an increase at the end of 
observation (Table 2).
Ovarian cancer
OC incidence varied from 7.9 to 2.2, and the mortality rate 
ranged from 6 to 9.8. OC incidence increased from 1980 
to 1994 (AAPC 2.98, P0.05). During the same period, a 
significant but moderate increase in OC mortality was also 
found (AAPC 0.52, P0.05) (Table 1, Figure 3). From 
1994 until the end of the study, we observed a decrease in 
both OC incidence (AAPC -0.49, P0.05) and mortality 
(AAPC -0.66, P0.05) (Table 1, Figure 3).
Age-related analysis of OC incidence showed descending 
trend lines among women 34 years old during the study 
period. In women 35–59 years old, we observed a large, 
significant increase in OC incidence until the early 1990s, 
followed by a moderate, significant decrease until the end of 
the study period (Table 2).
Table 1 incidence and mortality of breast, corpus uteri, and ovarian cancers in Poland, 1980–2013
Years Breast cancer (174§/C50§§) Corpus uteri cancer (182§/C54§§) Ovarian cancer (183§/C56§§)
Incidence Mortality Incidence Mortality Incidence Mortality
n CR ASR n CR ASR n CR ASR n CR ASR n CR ASR n CR ASR
1980 5,154 28.3 23 3,446 18.9 14.8 1,524 8.4 6.7 702 3.9 2.8 1,734 9.5 7.9 1,464 8 6.5
1981 – – – – – – – – – – – – – – – – – –
1982 5,120 27.6 22.3 3,641 19.6 15 1,547 8.3 6.6 716 3.9 2.8 1,830 9.9 8.3 1,397 7.5 6
1983 5,386 28.7 23.1 3,664 19.5 14.8 1,796 9.6 7.5 726 3.9 2.8 1,856 9.9 8.1 1,478 7.9 6.2
1984 – – – – – – – – – – – – – – – – – –
1985 6,147 32.3 26.1 3,795 19.9 15.1 2,029 10.6 8.4 714 3.7 2.6 2,150 11.3 9.4 1,522 8 6.3
1986 – – – – – – – – – – – – – – – – – –
1987 – – – – – – – – – – – – – – – – – –
1988 6,513 33.6 26.8 4,045 20.9 15.5 2,200 11.3 8.8 758 3.9 2.7 2,333 12 9.7 1,731 8.9 6.9
1989 6,706 34.5 27.5 4,097 21.1 15.5 2,166 11.1 8.5 702 3.6 2.5 2,370 12.2 9.9 1,718 8.8 6.8
1990 6,649 34 26.8 4,323 22.1 16.1 2,301 11.8 9 763 3.9 2.6 2,404 12.3 10 1,747 8.9 6.8
1991 7,343 37.4 29.2 4,198 21.4 15.5 2,626 13.4 10.1 776 4 2.7 2,680 13.7 10.9 1,787 9.1 6.9
1992 7,671 39 30 4,429 22.5 16.2 2,611 13.3 10.1 781 4 2.6 2,765 14.1 11.2 1,850 9.2 6.9
1993 8,416 42.6 32.3 4,381 22.2 15.7 2,858 14.5 10.9 724 3.7 2.4 2,982 15.1 12 1,880 9.5 7.2
1994 8,458 42.8 32.3 4,449 22.5 15.9 3,001 15.2 11.3 762 3.9 2.5 2,876 14.5 11.3 1,794 9.1 6.6
1995 9,173 46.3 35.3 4,665 23.6 16.3 2,980 15 11.3 763 3.9 2.5 2,993 15.1 11.8 1,840 9.3 6.8
1996 9,681 48.8 35.9 4,738 23.9 16.1 3,043 15.3 11.1 842 4.2 2.7 3,220 16.2 12.2 1,909 9.6 6.7
1997 – – – – – – – – – – – – – – – – – –
1998 – – – – – – – – – – – – – – – – – –
1999 10,903 54.9 38.8 4,553 22.9 14.8 3,260 16.4 11.4 761 3.8 2.3 3,151 15.9 11.4 1,959 9.9 6.7
2000 11,853 59.7 41.8 4,712 23.7 15 3,496 17.6 12 808 4.1 2.4 3,157 15.9 11.2 2,032 10.2 6.7
2001 12,118 61 42.4 4,825 24.3 14.9 3,675 18.5 12.4 776 3.9 2.2 3,193 16.1 11.2 2,152 10.8 6.9
2002 12,132 61.5 42 4,825 24.5 15 3,796 19.3 12.6 757 3.8 2.2 3,267 16.6 11.3 2,171 11 6.9
2003 11,733 59.6 40.2 4,942 25.1 15 3,953 20.1 13 783 4 2.2 3,371 17.1 11.5 2,271 11.5 7.1
2004 12,049 61.2 40.7 4,887 24.8 14.5 4,193 21.3 13.4 794 4 2.2 3,264 16.6 10.9 2,273 11.5 7
2005 13,385 67.9 44.5 5,112 26 14.9 4,196 21.3 13.3 770 3.9 2 3,355 17 11.1 2,357 12 7
2006 13,322 67.6 44.2 5,212 26.5 14.8 4,376 22.2 13.7 814 4.1 2.2 3,291 16.7 10.8 2,390 12.1 7
2007 14,484 73.5 47.7 5,255 26.7 14.6 4,640 16.3 10.4 848 4.3 2.2 3,214 16.3 10.4 2,485 12.6 7.2
2008 14,576 74 47.2 5,362 27.2 14.7 4,820 16.6 10.6 952 4.8 2.4 3,280 16.6 10.6 2,507 12.7 7.1
2009 15,752 79.8 50.4 5,241 26.6 14.1 5,061 17.6 11.1 969 4.9 2.4 3,474 17.6 11.1 2,510 12.7 7
2010 15,784 79.4 49.6 5,226 26.3 13.7 5,125 18.1 11.3 1,042 5.2 2.5 3,587 18.1 15.2 2,547 12.8 9.9
2011 16,534 83.2 51.8 5,437 27.4 14.2 5,251 17.8 10.9 1,085 5.5 2.5 3,527 17.8 14.6 2,558 12.9 9.8
2012 17,000 85.5 51.9 5,574 28 14.1 5,426 17.8 10.8 1,162 5.8 2.7 3,544 17.8 14.6 2,432 12.2 9.1
2013 17,142 86.3 51.8 5,816 29.3 14.5 5,706 18.3 11 1,243 6.3 2.8 3,639 18.3 14.8 2,603 13.1 9.6
aaPc 
(ci)
1980–1990: 2.14$ 
(1.2 to 3.1)
1990–1996: 4.71$
(2.4 to 7.1)
1996–2013: 2.21$
(1.8 to 2.6)
1980–1994: 0.52$
(0.2 to 0.9)
1994–2013: -0.66$
(-0.9 to -0.5)
1980–1994: 3.70$
(3.2 to 4.2)
1994–2013: 1.93$
(1.6 to 2.2)
1980–2006: -1.12$
(-1.4 to -0.9)
2006–2013: 3.74$
(2.1 to 5.4)
1980–1994: 2.98$
(2.5 to 3.5)
1994–2013: -0.49$
(-0.8 to -0.2)
1980–1989: 1.13$
(0.1 to 2.2)
1989–2009: 0.19
(-0.1 to 0.5)
2009–2013: -1.60
(-4.4 to 1.2)
Notes: §Coding according to the International Statistical Classification of Diseases and Related Health Problems (ICD), ninth revision; §§coding according to the icD, tenth 
revision; $P0.05.
Abbreviations: CR, crude ratio; ASR, age-standardized ratio; AAPC, average annual percentage change; CI, confidence interval.
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Figure 3 standardized incidence and mortality trends in breast, corpus uteri, and ovarian cancers, 1980–2013.
Note: $P0.05.
Abbreviations: AAPC, average annual percentage change; CI, confidence interval.
− − −
−
− −
− − −
− − −
Table 2 The age-specific incidence and mortality of breast, corpus uteri, and ovarian cancers in Poland, 1980–2013
Age, 
years
Breast cancer trends# Corpus uteri cancer trends# Ovarian cancer trends#
Incidence Mortality Incidence Mortality Incidence Mortality
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
0–4 – – – – – –
5–9 – – – – – –
10–14 – – – – – –
15–19 – – – – 1980–2013: -1.06
(-2.5 to 0.4)
–
20–24 1980–2013: -2.1$
(-3.6 to -0.6)
– – – 1980–2013: -0.86
(-1.7 to 0)
1980–2013: -3.55$
(-6.0 to -1.1)
25–29 1980–2013: 1.17$
(0.4 to 1.9)
1980–2013: -3.12$
(-4.8 to -1.4)
– – 1980–2013: -0.2
(-1 to 0.6)
1980–2013: -3.59$
(-4.9 to -2.3)
30–34 1980–2013: 1.42$
(0.9 to 1.9)
1980–2013: -1.82$
(-2.6 to -1.1)
1980–2013: 1.44
(-0.5 to 3.4)
– 1980–2013: -0.45
(-1.1 to 0.2)
1980–2013: -2.51$
(-3.7 to -1.3)
35–39 1980–2013: 1.57$
(1.3 to 1.9)
1980–1991: -0.25
(-2.5 to 2.5)
1991–2013: -3$
(-3.7 to -2.3)
1980–2013: 1.79$
(0.9 to 2.7)
– 1980–1990: 0.05
(-2.9 to 3.1)
1990–1993: 6.65
(-23.6 to 48.8)
1993–2013: -1.29$
(-2.2 to -0.3)
1980–2013: -2.47$
(-3.0 to -2.0)
40–44 1980–1988: 4.82$
(2.4 to 7.3)
1988–2013: 1.24$
(1.80 to 1.5)
1980–1991: 1.6
(-0.3 to 3.6)
1991–2013: –2.84$
(-3.4 to -2.2)
1980–1996: 2.82$
(1.5 to 4.1)
1996–2001: -4.02
(-28.4 to 28.1)
2001–2013: 3.97$
(2.2 to 5.8)
1980–2013: -3.6$
(-4.7 to -2.4)
1980–1991: 3.62$
(1.9–5.4)
1991–2013: -1.39$
(-1.9 to -0.9)
1980–1992: 1.52
(-0.8 to 3.9)
1992–2013: -2.59$
(-3.5 to -1.7)
(Continued)
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Table 2 (Continued)
Age, 
years
Breast cancer trends# Corpus uteri cancer trends# Ovarian cancer trends#
Incidence Mortality Incidence Mortality Incidence Mortality
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
AAPC, %
(CI)
45–49 1980–1983: 
-1.24
(-8.4 to 6.5)
1983–1996: 4.81$
(3.6 to 6.1)
1996–2013: 0.27
(-0.4 to 0.9)
1980–1995: 0.66
(-0.2 to 1.5)
1995–2013: -2.69$
(-3.3 to -2.1)
1980–2013: 1.31$
(0.9 to 1.7)
1980–2013: -2.58$
(-3.5 to -1.7)
1980–1993: 3.37$
(2.5 to 4.3)
1993–2013: -1.18$
(-1.6 to -0.7)
1980–2013: -1.05$
(-1.5 to -0.6)
50–54 1980–1990: 1.32
(-0.1 to 2.8)
1990–2000: 6.34$
(4.5 to 8.2)
2000–2013: 0.77
(-0.1 to 1.6)
1980–1996: 0.29
(-0.4 to 1)
1996–2013: -1.75$
(-2.4 to -1.1)
1980–1993: 3.64$
(2.5 to 4.7)
1993–2013: 0.53$
(0 to 1.1)
1980–2013: -2.32$
(-2.9 to -1.7)
1980–1995: 3.1$
(2.2 to 4.0)
1995–2013: -0.95$
(-1.6 to -0.3)
1980–2013: -0.15
(-0.5 to 0.2)
55–59 1980–1992: 1.56$
(0.6 to 2.6)
1992–2001: 6.66$
(4.9 to 8.5)
2001–2013: 1.1$ 
(0.2 to 2.0)
1980–2002: 0.21
(-0.2 to 0.6)
2002–2013: -1.14
(-2 to -0.3)
1980–2002: 2.39$
(1.9 to 2.9)
2002–2013: 0.61
(-0.5 to 1.7)
1980–2006: -2.23$
(-2.8 to -1.7)
2006–2013: 3.5
(0 to 7.1)
1980–1995: 3.16$
(2.5 to 3.9)
1995–2013: -0.62$
(-1.1 to -0.1)
1980–2013: -0.02
(-0.2 to 0.2)
60–64 1980–1988: 1.31
(-1.1 to 3.7)
1988–2004: 3.65$
(3.1 to 4.2)
2004–2007: 
11.37
(-1.3 to 25.6)
2007–2013: 0.37
(-1.7 to 2.4)
1980–2013: 0.15
(-0.1 to 0.4)
1980–2009: 3.05$
(2.8 to 3.3)
2009–2013: -2.55
(-6.2 to 1.2)
1980–1983: 9.15
(-1 to 20.4)
1983–2000: -1.8$
(-2.9 to -0.7)
2000–2013: 1
(0 to 2.0)
1980–1996: 2.33$
(1.7 to 2.9)
1996–2013: 0.11
(-0.5 to 0.7)
1980–2013: 0.38$
(0.1 to 0.6)
65–69 1980–2003: 3.07$
(2.7 to 3.5)
2003–2013: 5.6$
(4.4 to 6.9)
1980–2013: 0.1
(-0.1 to 0.3)
1980–1993: 5.67$
(4.4 to 6.9)
1993–2013: 2.61$
(2.0 to 3.2)
1980–1996: 0.99$
(0 to 2)
1996–2004: -2.99
(-7.8 to 2.1)
2004–2013: 4.66$
(2.5 to 6.9)
1980–1991: 4.01$
(2.2 to 5.9)
1991–2013: 0.65$
(0.1 to 1.2)
1980–2013: 1.09$
(0.8 to 1.4)
70–74 1980–1988: 1.15
(-1.4 to 3.8)
1988–1993: 6.94$
(2.6 to 11.4)
1993–2013: 1.43$
(1.0 to 1.8)
1980–1983: 10.91$
(3.1 to 19.4)
1996–2013: 0.04
(-0.2 to 0.3)
1980–1994: 6.53$
(5.6 to 7.4)
1994–2013: 2.98$
(2.4 to 3.5)
1980–2009: -0.11
(-0.5 to 0.3)
2009–2013: 12.04$
(4.5 to 20.1)
1980–1993: 4.47$
(3.1 to 5.9)
1993–2013: 0.51
(-0.2 to 1.2)
1980–2013: 1.62$
(1.3 to 1.9)
75–79 1980–1996: 3.95$
(3.0 to 4.9)
1996–2013: 1.83$
(0.9 to 2.8)
1980–1994: 2.04$
(1.4 to 2.6)
1994–2013: -0.04
(-0.4 to 0.3)
1980–2013: 4.19$
(3.8 to 4.6)
1980–2006: -0.13
(-0.7 to 0.5)
2006–2013: 4.82$
(0.8 to 9.0)
1980–2002: 4.77$
(3.8 to 5.8)
2002–2013: 0.4
(-0.3 to 1.1)
1980–2008: 2.77$
(2.4 to 3.2)
2008–2013: -2.36
(-6.6 to 2)
80–84 1988–2013: 2.39$
(2.0 to 2.8)
1980–2001: 1.89$
(1.3 to 2.5)
2001–2013: -0.31
(-1.4 to 0.8)
1980–1983: -6.19
(-20.4 to 10.5)
1983–2013: 4.56$
(4.0 to 5.2)
1980–2003: -0.11
(-1 to 0.7)
2003–2013: 3.79$
(1.2 to 6.4)
1980–2002: 3.58$
(2.7 to 4.4)
2002–2013: -0.22
(-2.2 to 1.8)
1980–2013: 2.87$
(2.5 to 3.5)
85+ 1988–2013: 1.51$
(0.7 to 2.4)
1980–1992: 1.51$
(0.3 to 2.8)
1992–2001: 4.42$
(2.2 to 6.7)
2001–2013: 0.18
(-0.9 to 1.3)
1980–2013: 3.17$
(2.5 to 3.8)
1980–2013: 1.98$
(1.2 to 2.8)
1980–1995: 5.8$
(4.1 to 7.5)
1995–2013: 0.3
(-1 to 1.6)
1980–2013: 3.58$
(2.8 to 4.4)
Notes: $P0.05; #missing data for 1981, 1985–1986, and 1997–1998.
Abbreviations: AAPC, average annual percentage change; CI, confidence interval.
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adjuvant radiotherapy followed by hormonal treatment in 
ER- and PR-positive women and immunotherapy in HER2-
positive patients resulted in improved therapeutic effects.
In Poland, CUC malignancies are the third-most common 
neoplasm affecting women following BC and lung cancer.28 
Recent research has shown a decline in nonendometrioid 
uterine adenocarcinomas and stable incidence rates for uter-
ine sarcomas and carcinosarcomas; therefore, the increase in 
CUC is most likely caused by an upsurge in endometrioid 
adenocarcinomas.29 Our results are consistent with data from 
two studies reporting an increase in the incidence of endo-
metrial cancer in the UK and Norway.30,31 However, another 
study showed relatively constant incidence of endometrioid 
adenocarcinoma in the Netherlands.32 On the other hand, 
a reduction in endometrioid adenocarcinoma mortality was 
observed in Germany, the UK, Norway, and France, as well 
as the US.31,32 Interestingly, subsequent detailed analyses 
showed that CUC mortality increased among women over 
54 years old from the late 1990s to the early 2000s, followed 
by a decrease. However, these findings may be related to an 
increase in lifestyle-related comorbidities that overwhelm 
favorable disease prognoses and health care improvements, 
and thus need further evaluation.
Ovarian epithelial tumors are responsible for the vast 
majority of ovarian malignancies, as ovarian germ cells 
and sex-cord tumors are in the minority and have a stable 
incidence and mortality rate.32,33 Our study confirmed a small 
but significant decrease in OC incidence from the mid 1990s 
that resulted in a slight but insignificant decline in mortality 
rate. Similar results were found by Waldmann et al, who 
reported a decrease in incidence and mortality of OC among 
a German population during the last two decades.34 Another 
study reported stable OC incidence and mortality rates in 
Nordic countries for 1964–2003.35 Interestingly, despite the 
decreasing fertility rate and parity, we observed a decrease 
in the OC incidence in the analyzed population. Additional 
analyses, however, showed an increasing incidence among 
women over 59 years old. On the other hand, there was 
a gradual decrease in OC incidence among women aged 
35–59 years beginning in the early 1990s. Women aged 
20–40 years use hormonal contraception as first-choice birth 
control, and although detailed data concerning prescribing 
hormonal contraception were unavailable, this is a strong 
protective factor playing a pivotal role in reduction in OC 
incidence despite reduced parity.36
Although our results are consistent with data from other 
studies among European and North American populations, 
several limitations exist. For example, in this study, cancers 
In women younger than 55 years, we observed a signifi-
cant decrease in OC mortality, except among patients aged 
40–44 years, who showed an insignificant increase between 
1980 and 1992 (Table 2). OC mortality remained stable 
among women aged 55–59 years for the entire study period. 
However, in women over 59 years old, significantly increas-
ing OC mortality trends were present, with slopes differing 
from low to high (Table 2).
Discussion
This study provides population-based information on inci-
dence and mortality trends for BC, CUC, and OC during 
the years 1980–2013 among the female Polish population. 
This study confirmed changes in incidence and mortality 
trends for all the analyzed cancers among the total sample, 
as well as by age.
The incidence of BC is increasing worldwide, predomi-
nantly in developed countries, results that are supported by 
our findings. For example, Torre et al reported an increase 
in the age-standardized incidence of BC (35–135) among 
women in the US in 1992–2012, and an increase in the inci-
dence of BC was also reported in the Nordic countries, UK, 
Germany, and France.23–25 This may be because increasing 
income, which acts as a surrogate for economic factors, 
along with decreasing fertility and birth rates, promoted a 
rise in BC incidence in the studied population. Furthermore, 
in women born after 1920, the BC mortality rate was stable 
or started to decline in 18 European countries, the US, and 
Canada.26 These data are consistent with Levi et al, who 
found that BC mortality decreased in 38 countries during 
1970–2000.27 Results from these studies are in agreement 
with our findings, which showed an increase in BC mortality 
among Polish women until 1994, followed by a significant 
though minimal decrease. Furthermore, a significant, large 
decrease in BC mortality was observed among young women 
with BC during the analyzed period. The decrease in BC 
mortality observed in the welfare population is a result of 
diagnostic and treatment improvement. 
In 2006, Poland started a national screening program 
against BC for women aged 50–69 years and based on screen-
ing mammography every 2 years.28 As the program ran for 
only 10 years, with response rates varying between 35% and 
50% depending on region (still lower than the 70%–75% 
response rate recommended by the World Health Organiza-
tion), its population effects in decreased mortality will be 
due to occur in the next two or three decades.28 However, 
the awareness of BC in women is rising. Additionally new 
surgical modalities, including breast-conserving therapy with 
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were not classified histologically. Therefore, we could not dis-
tinguish between type I and II endometrial cancers nor between 
uterine sarcomas. While CU sarcomas account for 6%–8% 
of uterine cancers, type II endometrial cancer accounts for 
another 20%, and thus most data reflect the trends of endome-
trial cancer. Similarly, we were unable to distinguish between 
epithelial and nonepithelial OC. In addition, tumor grading 
and staging data were also unavailable for general access 
in the PNCR. Although such a detailed and comprehensive 
analysis would be of great interest for many physicians and 
epidemiologists, not including this information did not affect 
the final results in our opinion. Moreover, data were missing 
for 5 years of the total 34-year period. However, these missing 
data were scattered throughout the study period, limiting any 
influence on bias in the final analysis. Furthermore, changes 
to the ICD classification during the study period may have 
introduced a reporting bias; however, we did not observe a 
significant difference in incidence and mortality rates after the 
ICD change, indicating a lack of reporting bias. Additionally, 
socioeconomic data were not directly related to cancer cases; 
therefore, a straight-line analysis of their possible impact on 
incidence and mortality rates was impossible. Therefore, 
these data should be considered as surrogates of socioeco-
nomic changes in the population, rather than having a direct 
impact on particular cancer cases. Finally, the completeness 
of reported data is essential to cancer epidemiology. World 
Health Organization recommended incidence/mortality rate 
as a simple tool for evaluating registry comprehensiveness. 
Completeness of registration is defined as estimated percent-
age of registered cancers, and calculated as follows:28
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In 1990, when data collection was computerized, 
incidence/mortality rate in women was 1.25 (lower com-
pared to Finland, with its good cancer registry similar to the 
Polish population, where this ratio was 1.58) with 80% of 
registration completeness.28 Since then, a gradual increase in 
completeness of reports has been observed, with incidence/
mortality rate in the female population reaching 1.55 in 
2011 with 94% completeness and 1.67 in 2013 for the total 
population (separate data for female population and com-
pleteness were not published).28 Although that completeness 
of registered cancer incidence improved significantly, the 
PNCR still recommend the term “registered incidence” 
instead of “incidence”, as incidence data are still biased by 
underregistration.28
The strength of this study are reliable data on cancer 
mortality, as the PNCR collects mandatory cancer-death noti-
fication. Therefore, the 34-year-long study period allowed 
for a comprehensive and accurate mortality-trend analysis, 
even if data in some years were missing.
Conclusion
The results of the present study indicate a significant increase 
in the incidence of BC and CUC, while the incidence of 
OC initially increased and then decreased. Fortunately, the 
mortality rates for women with BC, CUC, and OC decreased 
in the last decade of the study. The data also showed that 
age, apart from the type of malignancy, was the major factor 
influencing incidence and mortality trends.
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